STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the World Health Organization. This study analyzed factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the short regimen. The factors associated with FoR outcomes identified in this study should be considered when determining the optimal shortened treatment regimen.
Published: August 1, 2022
Sign up to receive our monthly Research Roundup email, which offers a selection of new public health research from major journals.
Recent Abstracts
Analysing India’s Unique Subnational WHO FCTC Article 5.3 Policies and Their Implementation Across 17…
Strengthening the Tobacco Cessation Ecosystem
Activity Report 2025 – Brazil
More Data Better Health – Brazilian People’s Perceptions of Risk Factors for Cancer
Relatório de Atividades 2025 – Brasil
Mais Dados Mais Saúde – Percepções da população brasileira sobre fatores de risco…
What Primary Care Records Reveal About Cancer Signs and Symptoms
O que os prontuários da atenção primária revelam sobre sinais e sintomas de…
CRVS Performance Measurement and Monitoring Resource Kit
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council